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Abstract
Background: Ov16 serology is considered a reference method for Onchocerca volvulus epidemiological mapping.
Given the suboptimal sensitivity of this test and the fact that seroconversion takes more than a year after infection,
additional serological tests might be needed to guide onchocerciasis elimination programmes. Recently, two linear
epitopes encoded in OvMP-1 and OvMP-23 peptides were introduced as serological markers, but the observed antibody
cross-reactivity in samples originating from Onchocerca volvulus non-endemic areas required further investigation.
Methods: We evaluated both peptide markers in an O. volvulus hypo-endemic setting in Jimma Town, Ethiopia using
peptide ELISA. For all individuals (n = 303), the infection status with soil-transmitted helminths and Schistosoma mansoni
was known.
Results: We found that 11 (3.6%) individuals were positive for anti-Ov16 IgG4 antibodies, while 34 (11.2%) and 15 (5.0%)
individuals were positive for OvMP-1 and OvMP-23, respectively. Out of the 34 OvMP-1 positive samples, 33 were
negative on the Ov16 IgG4 ELISA. Similarly, out of the 15 OvMP-23 positive samples, 14 scored negative on this reference
method. No difference in seroprevalence for all three markers could be observed between uninfected individuals and
individuals infected with different soil-transmitted helminths or S. mansoni. Moreover, the intensity of the response to
OvMP-1, OvMP-23 or Ov16 was not significantly stronger in individuals carrying patent STH or S. mansoni infections,
nor was there any correlation between the intensities of the responses to the three different antigens.
Conclusions: This study demonstrates that a patent infection with either soil-transmitted helminths or S. mansoni does
not lead to increased antibody recognition of both OvMP-1 and OvMP23.
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Background
Onchocerciasis (river blindness) is one of the 20 debilitat-
ing neglected tropical diseases (NTDs) that have been
listed by the World Health Organization (WHO) [1–3].
Onchocerciasis is an eye and skin disease caused by
infection with the filarial worm Onchocerca volvulus.
Worldwide there are 198 million people at risk of oncho-
cerciasis, of which 99% live in Africa. In 2012 it was esti-
mated that 17 million people are affected by the disease or
at risk of infection in Ethiopia, making it one of the most
affected countries worldwide [4]. In 2013, the Ethiopian
government launched the Onchocerciasis Elimination
Programme aimed at nationwide interruption of transmis-
sion of the disease by 2020 [5]. This programme is based
on biannual mass drug administration (MDA) of the
microfilaricidal agent ivermectin (Mectizan, Merck & Co.,
Inc., Kenilworth, New Jersey, USA).
One of the largest epidemiological mapping efforts for
O. volvulus was conducted in 20 African countries,
called Rapid Epidemiological Mapping of Onchocerciasis
(REMO) in support of the African Programme for On-
chocerciasis Control (APOC). The main objective of
REMO was to identify all high-risk areas where ivermec-
tin treatment was needed. For this programme, diagnosis
was based on examination of 30 to 50 adults for the
presence of palpable onchocercal nodules in selected vil-
lages [6, 7]. Besides the detection of palpable nodules
and presence of microfilariae in skin biopsies, the most
widely used test for monitoring and evaluation of MDA
programmes currently is the detection of IgG4 anti-
bodies to the parasitic antigen Ov16 [8–15]. Although
such antibody test cannot distinguish between past and
current infections, the presence of anti-Ov16 antibodies
in young children provides evidence for recent exposure
[8]. Several studies have shown that Ov16 IgG4 testing is
useful for assessing ongoing transmission of onchocer-
ciasis following MDA in Latin America and Africa [15].
However, although Ov16 IgG4 serology has excellent
specificity, it appears to have only moderate sensitivity.
Sensitivity further decreases when the rapid diagnostic test
(RDT) for the detection of Ov16 IgG4 antibodies is used
[8, 9, 11]. Discussions are ongoing about the threshold
that should be used to determine when it is safe to stop
MDA based on Ov16 seroprevalence [16, 17]. Current
guidelines indicate 0.1% Ov16 serology in children under
10 years of age, but this is neither practical nor pos-
sible with the current Ov16 based tools as even a
specificity of 97–98% is not sufficient to enable reli-
able detection of < 0.1% prevalence [10, 11].
Recently, two peptide-based serology markers
(OvMP-1 and OvMP-23) were described and their diag-
nostic performance evaluated [18]. Both peptides
showed high diagnostic sensitivity (100% and 92.7%, re-
spectively) and specificity (98.7% and 100%, respectively).
Neither of these peptides showed significant
cross-reactivity in sera from Wuchereria bancrofti-in-
fected individuals. However, especially for peptide
OvMP-1, substantial reactivity was detected in samples
originating from Indonesian individuals infected with
Brugia malayi or soil-transmitted helminths (STHs).
Due to the small sample set (B. malayi-infected: n = 20;
STH-infected: n = 20) and the limited background infor-
mation available on these individuals, a more thorough
investigation into the cross-reactivity of these diagnostic
peptides in Onchocerca endemic and non-endemic set-
tings towards STH infections was necessary.
The development of newly discovered biomarkers as
diagnostic tools depends largely on the proven clinical
utility of these biomarkers. In the first phase of biomarker
validation, the analytical validation, it is key to determine
the sensitivity and specificity of a biomarker. Therefore,
biobanks containing samples from clear-cut cases and
controls should be obtained and evaluated. Additionally,
especially in the field of infectious diseases, there is a need
to confirm that the biomarker is not affected by closely re-
lated conditions. In the case of biomarkers for onchocer-
ciasis, it is of absolute importance to evaluate novel
biomarkers in individuals that are infected with other hel-
minths, such as W. bancrofti and B. malayi, causing
lymphatic filariasis (LF), soil-transmitted helminths
(STHs) or schistosomes, but live in non-, hypo- or
meso-endemic areas for Onchocerca (0%, < 20%, and be-
tween 20–45% nodule prevalence in adult males, respect-
ively [6]). In this study, we specifically evaluated the
reactivity towards the serological markers OvMP-1 and
OvMP-23 in an area in Ethiopia that is highly endemic for
STH and S. mansoni, but hypo-endemic for Onchocerca.
Methods
Study site and study population
The samples used in this study originated from the popu-
lation of Jimma Town, south-west Ethiopia and were ori-
ginally collected as part of a study focused on STH
diagnostics (Dana et al., unpublished data). Jimma Town is
considered a hypo-endemic area for O. volvulus, but with
moderate to high infection rates for STHs and S. mansoni
[19–22]. Although the prevalence of onchocerciasis in the
population of Jimma Town itself is generally very low,
MDA with ivermectin is ongoing since 2014. Moreover,
Jimma Town is non-endemic for other filarial infections
including Mansonella perstans [23], Loa loa [24] or
Wuchereria bancrofti [4, 25]. Study participants were
school-aged children (aged 5 to 18 years) and adults (18 to
70 years-old) living within the city limits of Jimma Town.
Sample collection
The participants of the study were asked to provide a
single stool sample of at least 5 g of stool in a clean,
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labeled stool container. To limit the number of false
negative samples, all samples were processed using the
Kato-Katz thick smear (0.0417 g), Mini-FLOTAC (2 g of
stool) and McMaster egg counting method (2 g of stool)
for the detection and enumeration of STH and S. man-
soni eggs. Individuals were considered to be infected
with STHs or S. mansoni if any of the three coprological
techniques showed the presence of worm eggs. Individ-
uals that were positive for more than one helminth spe-
cies were categorized as having a mixed infection. An
overview of the number of samples distributed by age
and helminth infection is provided in Table 1. In
addition, 2 ml of venous blood was collected and follow-
ing centrifugation, serum samples were separated and
stored at -20 °C before shipping to the laboratory of
parasitology of Ghent University, Belgium for ELISA
evaluation. All collected coprological and serological
data of all evaluated samples are available in
Additional file 1: Table S1.
Total IgG peptide ELISA for OvMP-1 and OvMP-23
C-terminally biotinylated synthetic peptides OvMP-1
(VSV-EPVTTQET-VSV) and OvMP-23 (VSV-KDGE
DK-VSV-QTSNLD-VSV) were synthesized by standard
procedures and purchased from PEPperPRINT GmbH
(Heidelberg, Germany). For determination of peptide spe-
cific serum antibody levels, a peptide ELISA was devel-
oped and set up as described previously [18, 26]. The
cut-offs for OvMP-1 and OvMP-23 were previously deter-
mined and were set at background-corrected OD values
of 0.045 and 0.110, respectively [18].
Ov16 IgG4 ELISA
Recombinant O. volvulus Ov16 antigen was purchased
from Cusabio Biotech Co., Ltd (College Park, MD, USA)
and dissolved in water at a concentration of 1 mg/ml. For
determination of Ov16 specific IgG4 levels, an ELISA was
developed and set up as follows. Maxisorp 96-well plates
were incubated overnight at 4 °C with 100 μl of Ov16 anti-
gen, diluted at 1 μg/ml in PBS. The plates were rinsed once
with 300 μl PBS + 0.05% Tween-20 (washing buffer), before
being blocked with 300 μl of Superblock™ Blocking Buffer
(Thermo Fisher Scientific, Breda, the Netherlands) for 1 h
at room temperature. The plates were rinsed 3 times with
washing buffer. Then, the different wells were covered with
100 μl of human serum samples, diluted 200-fold in Block-
ing Buffer. In “blank” control wells, Blocking Buffer was
added instead. The plate was incubated at room
temperature for 1 h. After incubation, a 5-fold rinsing cycle
with washing buffer was performed. Then, the secondary
antibody solution was added to each well. The solution
contained a mouse monoclonal HP6025 Anti-Human IgG4
(HRP) from Abcam (Cambridge, UK) diluted 1:10,000 in
Blocking solution. The reaction mixture was incubated at
room temperature for 30 min. Subsequent steps were the
same as for the peptide ELISA. The cut-off for positivity on
blank-corrected OD values was set at 0.10. Using that
cut-off, the ELISA had a sensitivity of 58.6% and a specifi-
city of 100% based on a set of samples from 99
nodule-positive individuals from Ghana and 9 healthy west-
ern controls. These performance characteristics are in line
with other Ov16 IgG4 tests [8–15].
Statistical analysis
To compare the antibody responses between different
groups, Kruskal-Wallis test was performed. For assess-
ment of correlation among responses, Spearman’s correl-
ation coefficients and one-tailed P-value were calculated.
In order to investigate trends in seropositivity over differ-
ent age groups, a Chi-square test for trend was calculated.
To determine the overrepresentation of prevalence in a
certain group, contingency tables were prepared, and
Chi-square test was performed. All analyses were per-
formed using GraphPad Prism 7.
Results
In total, serum samples of 303 subjects were investigated
in this study including 187 children and 116 adults. Sam-
ples were selected based on their STH infection status, as
determined by coprological examination. A total of 47
(17.5%) individuals were Ascaris lumbricoides single in-
fected, 61 (20.1%) were Trichuris trichiura single infected,
15 (5.0%) were single hookworm infected, 5 (1.7%) were
single S. mansoni infected, and 79 (22.4%) were infected
with more than one helminth species (mixed infection).
Additionally, 96 (31.7%) samples were included from indi-
viduals without patent infection with STH or S. mansoni
(Table 1 and Additional file 1: Table S1).
Table 1 Age category and STH infection status of study population used in this study
Age group (years) n A. lumbricoides
infected (n)
T. trichiura
infected (n)
Hookworm
infected (n)
S. mansoni
infected (n)
Mixed
infection (n)
Absence of patent
infection (n)
< 10 87 17 20 3 2 25 20
14–17 86 8 22 5 1 27 23
18–24 50 10 4 6 2 14 14
> 24 80 12 15 1 0 13 39
Total 303 47 61 15 5 79 96
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Total IgG against OvMP-1 and OvMP-23 and IgG4
levels against Ov16 were measured by ELISA. It was
found that 34 (11.2%) samples were positive for
OvMP-1, 15 (5.0%) for OvMP-23, and 11 (3.6%) for
Ov16 IgG4 (Fig. 1). To investigate whether seropreva-
lence for either OvMP-1, OvMP-23 or Ov16 was linked
to having a specific patent infection, samples were
grouped according to known helminth infection. No sig-
nificant difference in seroprevalence could be detected
among the different groups for either of the three ELI-
SA’s, as based on Chi-square test (OvMP-1: χ2 = 3.39, df
= 5, P = 0.64; OvMP-23: χ2 = 5.266, df = 5, P = 0.38; and
Ov16: χ2 = 7.14, df = 5, P = 0.21). Also, when grouping
all samples from individuals with any patent STH and/or
S. mansoni infection and comparing them with samples
from individuals without any patent infection, no signifi-
cant difference was found (OvMP-1: χ2 = 0.7596, df = 1,
P = 0.38; OvMP-23: χ2 = 0.5043, df = 1, P = 0.48 and
Ov16: : χ2 = 0.9613, df = 1, P = 0.33). Moreover, the in-
tensity of the response to OvMP-1 or OvMP-23 was not
significantly stronger in individuals carrying patent STH
or S. mansoni infections compared to individuals with-
out a patent infection (Fig. 1). For Ov16 IgG4, there was
a significant difference in the intensity of the response
between the different groups (Kruskal-Wallis test, P <
0.0001). However, due to the limited number of positive
samples (11 out of 303), these results should be inter-
preted with some reservation.
In total, 33 out of 34 individuals (97.1 %) that tested
positive for OvMP-1 and 14 out of 15 individuals (93.3
%) that tested positive for OvMP-23 were Ov16 negative.
To determine whether the reactivity to OvMP-1 or
OvMP-23 in Ov16 negative individuals was affected by
the presence of STH or S. mansoni infection, Chi-square
tests were performed. These tests showed that there was
no significant effect of infection with STH or S. mansoni
on providing a positive result on OvMP-1 or OvMP-23
peptide ELISA in Ov16 negative individuals (STH: χ2 =
0.5004, df = 1, P = 0.48 and χ2 = 0.526, df = 1, P = 0.47
and S. mansoni: χ2 = 0.7509, df = 1, P = 0.39 and χ2 =
1.317, df = 1, P = 0.25, respectively).
Although S. mansoni eggs were detected in the stool
of 26 individuals (8.6%), 21 of these individuals were har-
boring at least one other helminth species and were thus
included in the mixed infection group. From all 26 S.
mansoni infected individuals, 4 were positive for
OvMP-1 antibodies. None of these 4 individuals were in-
fected with only S. mansoni and all were negative for
Ov16 IgG4. In addition, none of the 26 S. mansoni in-
fected individuals had antibodies to OvMP-23.
No correlation was seen between the results obtained
from the Ov16 IgG4 and OvMP-1 or OvMP-23 IgG ELI-
SAs. A mutual correlation was observed between the
two peptide serology markers (Spearman’s r = 0.478, P <
0.0001). However, this correlation is mainly driven by
the high number of samples that were negative for both
markers (259 out of 303) but which showed correlating
background signals. This positive correlation disappears
if the analysis is performed only including samples that
were positive for one of both peptide markers.
When individuals were grouped according to different
age categories (< 10, 14–17, 18–24 and > 24 years), a
significant increase in seropositivity for OvMP-1 can be
observed in increasing age groups (Chi-square test for
trend: χ2 = 9.089, df = 1, P = 0.0026), while for
OvMP-23 and Ov16 IgG4 no significant differences
(Chi-square test for trend: χ2 = 0.2279, df = 1, P = 0.63
and χ2 = 0.1508, df = 1, P = 0.70, respectively) were ob-
served (Fig. 2). Although it might appear that for Ov16
and OvMP-23 seropositivity first increases and from the
age of 18 onwards decreases, this trend is not significant.
This might be due to the very low number of seroposi-
tive samples in each age group. In the group of children
under 10 years of age (n = 87), only 3 were positive for
Fig. 1 ELISA measurements of the antibody responses to OvMP-1 (IgG), OvMP-23 (IgG) and Ov16 (IgG4) in sera from study participants from
Jimma Town (Ethiopia). Participants are grouped according to the type of helminth infection that was detected by coprological examination. The
dashed lines indicate the antigen-specific cut-offs: 0.045 for OvMP-1; 0.11 for OvMP-23 and 0.10 for Ov16. Abbreviations: Al: A. lumbricoides; Tt:
Trichuris trichiuris; Hw: Hookworm; Sm: Schistosoma mansoni
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Ov16 IgG4. Moreover, the respective OD values of these
samples were between 0.1 and 0.2, which is barely across
the selected cut-off value for the Ov16 ELISA. In this
same age category, 4 (4.6%) tested positive for OvMP-1
and 3 (3.5%) tested positive for OvMP-23 antibodies.
Discussion
The assessment of cross-reactivity with other related and/
or co-endemic infectious agents is a critical part of the
analytical validation of novel diagnostic tools. Hence, this
work represents an essential part of the analytical valid-
ation of the serological markers OvMP-1 and OvMP-23.
We investigated the prevalence of antibodies against O.
volvulus antigens in Jimma Town, an urban setting in the
southwestern part of Ethiopia. Ethiopia is a country that
has been identified as endemic for O. volvulus for many
years [19]. Jimma Town itself is considered hypo-endemic
for onchocerciasis. Using the anti-Ov16 IgG4 ELISA, ex-
posure to Onchocerca was determined for all individuals
(n = 303). Using this standard assay, the overall seroposi-
tivity rate for O. volvulus in our study population was
3.6%, which suggests a hypo-endemic transmission setting
[6]. When focusing on the children under 10 years of age,
a seroprevalence of 3.5% was observed. This finding indi-
cates low prevalence of O. volvulus exposure but is still
considerably higher than the target seroprevalence of 0.1%
in the age group under 10 years as set by the WHO to de-
fine end of transmission and elimination [14, 27]. This is
also still above the threshold of 1% or even 2%, which has
recently been proposed as a more feasible threshold with
the current Ov16 based tools [16, 17]. However, it is of im-
portance to note that the Ov16 ELISA used in this study is
a research-use only test that has not yet been subjected to
a cross-validation with the original Ov16 ELISA or lateral
flow assays. It remains possible that the use of slightly dif-
ferent technology led to different seropositivity rates.
Using the newly identified serodiagnostic peptide anti-
gens OvMP-1 and OvMP-23, respectively 11.2% and
5.0% of investigated individuals tested positive. As de-
scribed before, both peptide ELISAs were not 100% spe-
cific for O. volvulus and also appeared to provide a
positive signal in individuals that were infected with
Brugia malayi, Wuchereria bancrofti or STHs [18]. Of
the samples that were seropositive for OvMP-1 (n = 34)
or OvMP-23 (n = 15), 97.1% and 93.3%, respectively,
were seronegative for anti-Ov16 IgG4 antibodies. How-
ever, these samples were not correlated to having a pa-
tent infection for STH or S. mansoni, indicating that
carrying a patent STH or S. mansoni infection does not
increase the chances of having antibodies that react with
either OvMP-1 or OvMP-23. These individuals were
therefore either truly exposed to O. volvulus but missed
by the Ov16 IgG4 ELISA or infected with other agents
that cause cross-reactivity with these peptides.
Based on the work presented here, the reactivity that
was previously observed to OvMP-1 in STH infected indi-
viduals from Flores (Indonesia) is likely caused by an im-
munological agent other than STH or Schistosomes [18].
For OvMP-23 the data presented here confirm the previ-
ous observations that STH infected individuals do not
have measurable antibody responses to the peptide [18].
Interestingly, in this area that is hypo-endemic for
Onchocerca, it appeared that the peptide serology
markers OvMP-1 and OvMP-23 did not mutually correl-
ate, nor did they correlate with the Ov16 IgG4. It is not
clear what the underlying cause is for this absence of
correlation. Since no true gold standard diagnostic test
exists for infection with O. volvulus, it is difficult to draw
conclusions about the samples that have discordant re-
sults for these serological markers. It is possible that
recognition of the three markers is affected by different
life-cycle stages or sex of the present parasite. Alterna-
tively, this might also reflect individual differences in
MHC Class II haplotypes [28, 29]. A combination of the
serological markers might be needed to properly define
infection status. Similar observations were also made in
a study where a set of four O. volvulus recombinant pro-
teins were evaluated as serological markers, and where
correlation between these markers was also often very
weak [30]. One explanation for the lack of correlation
between Ov16 IgG4 and the peptide markers might be
found in the fact that it takes on average 15 months be-
fore an Ov16 IgG4 response can be detected, while an
IgG response might already be observed 16 weeks after
exposure [31, 32]. While this is a drawback of IgG4-based
tests, it has the advantage of showing very high speci-
ficity [33].
Fig. 2 The percentage of seropositive individuals for OvMP-1,
OvMP23 and Ov16 according to age group
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While Ov16 seroprevalence was low over all the age
groups, for OvMP-1 there appeared to be a significant
trend towards increased seroprevalence as age increases.
This type of trend is typically attributed to ongoing
transmission settings where development of antibodies is
slow and prevalence is higher in the adult population
[34]. For OvMP-23 there also appeared to be an increase
in the age group between 14 and 18 years, which would
indicate ongoing transmission. However, seroprevalence
for OvMP-23 decreased again with increasing age, al-
though not significantly. It is well known that immune
responses against certain antigens can be shorter lived
than responses against other antigens [35, 36]. There-
fore, this pattern might be indicative of the shorter lon-
gevity of OvMP-23 antibodies, resulting in a stabilization
or even reduction in seroprevalence in higher age
groups. These patterns might however also indicate that
both Ov16 and OvMP-23 are specifically related to O.
volvulus for which transmission in the studied area is
low or even interrupted. In addition to exposure to O.
volvulus, antibody reactivity to OvMP-1 and OvMP-23
might also be stimulated by other, yet undefined agents
or organisms. Future evaluations with these diagnostic
peptides are required to help elucidate the possible ori-
gin of cross-reactive signals.
Conclusions
This work demonstrates that individuals with patent STH
or S. mansoni infections have no higher prevalence of
antibodies to both OvMP-1 and OvMP23 onchocerciasis
peptide markers compared to uninfected individuals. This
is an important aspect in the analytical validation of these
biomarkers. However, more work is needed to evaluate
the clinical utility of the selected peptide ELISAs in Onch-
ocerca endemic and non-endemic populations, and to fur-
ther investigate the origin of the discordancy with the
Ov16 ELISA test and their mutual discordancy.
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